GeoVax Advances Mpox Vaccine Candidate
GeoVax is advancing its GEO-MVA vaccine candidate to address a global mpox supply shortage. A Phase 3 trial is planned for late 2026 to provide a second-source solution. Further studies and trials are expected to follow.
Topics
Developing
- 865d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 865d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 865d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 865d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Source Alpha
Source Bravo
Source Charlie
Source Delta
Source Echo
Source Foxtrot
Source Golf
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade